MOHLTC - News Release - Ontario Second Province to Make New Drug Available to Fight Largest Cause of Blindness

Skip Navigation Menu

Government of Ontario Central Web Site

Ontario Ministry of Health and Long-Term Care

Return to Home Page
(External)

Government of Ontario Central Web Site

Site map

Version française de cette site web

Information Channels Public Information Health Care Providers News Media Text Only Version

Index

Skip column one

News Release
Ontario Second Province to Make New Drug Available to Fight Largest Cause of Blindness Lucentis will be added to provincial drug formulary this month

News Release Printable Version [PDF]

March 13, 2008

NEWS

Ontarians suffering from the leading cause of blindness in Canada will now have access to the new prescription medicine Lucentis.

Neovascular (wet) age-related macular degeneration (AMD) is a degenerative condition affecting central vision in people typically aged fifty and older. Lucentis works to maintain and even improve vision affected by wet AMD.

Today’s investment of over $100 million over three years means that Ontarians suffering from AMD will for the first time have access to this groundbreaking drug.

QUOTES

“Many people in Ontario, especially older people, will enjoy improved eyesight and quality of life with the availability of Lucentis through our publicly funded drug programs,” said George Smitherman, Deputy Premier and Minister of Health and Long-Term Care.

"We are extremely pleased that Lucentis, a product proven to prevent blindness, is being covered by Ontario's public drug programs," said Jim Sanders, CEO and president of CNIB. "I know that people with wet AMD, including many seniors, will be very happy with this announcement. It is clear that Ontario is establishing itself as a leader in meeting the needs of patients in need of important drug therapies."

“The decision to cover Lucentis is fantastic news for the people of Ontario that suffer from macular degeneration,” said Dr. Kyle Brydon, Chair of the Ontario Medical Association’s Section on Ophthalmology. “Lucentis is one of the most effective treatments for people suffering from the wet form of macular degeneration…The government’s decision to cover Lucentis will allow many more patients to be treated and potentially avoid the devastating impact of sudden, irreversible blindness.”

QUICK FACTS

Approximately 10,000 patients are treated for AMD in Ontario each year.
AMD affects the macula, an area of the retina responsible for detailed visual activities such as reading and facial recognition.
Since October 2003 the McGuinty government has added 86 new brand-name drugs available in 154 different strengths and formats – including Lucentis – to the Ontario Drug Benefit Formulary for reimbursement through the Ontario Public Drugs Programs. In addition, 15 drugs are reimbursed through the Exceptional Access Program.

LEARN MORE

(External) View a video of the announcement

Windows Media Icon

Backgrounder : Ontario Funds Lucentis for the Treatment of Wet Age-Related Macular Degeneration (AMD)

Members of the media :

Laurel Ostfield, 416-212-4048
Minister's Office

David Jensen, 416-314-6197
Ministry of Health and Long-Term Care

For more information

Media Line
Toll-free : 1-888-414-4774
In Toronto : 416-314-6197
If you are a reporter with a question for a story, or with comments about how this News Media section could serve you better, send us an email at : media@moh.gov.on.ca .

(External)

This site maintained by the government of Ontario, Canada.

Change Text Only Settings

Graphic version of this page